MedImmune to buy Cellective
MEDI will acquire antibody company Cellective (Gaithersburg, Md.) for an undisclosed sum in cash, plus potential milestones. The deal, which is expected to close in October, adds to MEDI's pipeline three MAbs against CD19, CD20 and CD22 that are in preclinical development to treat autoimmune diseases and cancer.
MEDI markets Synagis palivizumab, a first-generation MAb against RSV infection, and has several antibody products in development for infectious diseases and cancer. MEDI's Numax motavizumab is in Phase III testing for RSV, and BSYX-A110 is in Phase IIa testing to prevent serious bloodstream infections caused by staphylococcus in low birth weight infants. MEDI in-licensed BSYX-A110 from GlaxoSmithKline (LSE:GSK; GSK) earlier this month. ...